Estrogen receptor (ER) expression is inversely related to the grade of DCIS lesions [8] and targeting DCIS that express ER with tamoxifen significantly reduces risk of subsequent breast cancer by 40%–50% [45]. This evidence concerns the gene ESR1 and ductal breast carcinoma in situ.